Zacks Research Has Positive Outlook of Exelixis Q2 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Exelixis in a research note issued to investors on Monday, March 3rd. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn $0.47 per share for the quarter, up from their previous estimate of $0.46. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ FY2027 earnings at $3.20 EPS.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

A number of other brokerages have also recently commented on EXEL. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. UBS Group increased their target price on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Bank of America lowered Exelixis from a “buy” rating to a “neutral” rating and increased their target price for the company from $35.00 to $39.00 in a research report on Tuesday, December 17th. Finally, Stifel Nicolaus increased their target price on Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $38.65 on Wednesday. The stock has a market capitalization of $10.82 billion, a price-to-earnings ratio of 21.84, a PEG ratio of 1.13 and a beta of 0.57. Exelixis has a 12 month low of $20.14 and a 12 month high of $39.30. The firm’s 50 day simple moving average is $34.81 and its 200-day simple moving average is $31.91.

Insider Transactions at Exelixis

In other news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the transaction, the director now owns 30,406 shares in the company, valued at $1,060,561.28. The trade was a 28.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the transaction, the executive vice president now owns 341,028 shares in the company, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock worth $5,177,234 in the last quarter. Company insiders own 2.85% of the company’s stock.

Institutional Trading of Exelixis

Hedge funds and other institutional investors have recently modified their holdings of the business. Seizert Capital Partners LLC increased its position in shares of Exelixis by 8.0% during the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock worth $12,195,000 after purchasing an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC increased its position in shares of Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Tri Ri Asset Management Corp acquired a new stake in shares of Exelixis during the 3rd quarter worth about $4,396,000. CWA Asset Management Group LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth about $577,000. Finally, Blue Trust Inc. increased its position in shares of Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 8,208 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.